These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21339258)

  • 1. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
    Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
    [No Abstract]   [Full Text] [Related]  

  • 4. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
    Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
    Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival.
    Lee Y; Lee HJ; Kim YT; Kang CH; Goo JM; Park CM; Paeng JC; Chung DH; Jeon YK
    Korean J Radiol; 2013; 14(2):375-83. PubMed ID: 23483676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
    Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
    Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
    Ikushima H; Dong L; Erasmus J; Allen P; McAleer MF; Zhuang Y; Sasaki R; Komaki R
    J Radiat Res; 2010; 51(4):465-71. PubMed ID: 20508373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
    Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
    Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
    J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
    Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
    Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between EGFR mutation status and F
    Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
    Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
    Na II; Byun BH; Kim KM; Cheon GJ; Choe du H; Koh JS; Lee DY; Ryoo BY; Baek H; Lim SM; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of multiple metabolic and heterogeneity parameters of
    Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
    Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.